Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations

• Published in: Journal of thoracic oncology Vol. 16; no. 11; pp. 1952 - 1958
• Main Authors: Saalfeld, Felix C., Wenzel, Carina, Christopoulos, Petros, Merkelbach-Bruse, Sabine, Reissig, Timm M., Laßmann, Silke, Thiel, Sebastian, Stratmann, Jan A., Marienfeld, Ralf, Berger, Johannes, Desuki, Alexander, Velthaus, Janna-Lisa, Kauffmann-Guerrero, Diego, Stenzinger, Albrecht, Michels, Sebastian, Herold, Thomas, Kramer, Michael, Herold, Sylvia, Tufman, Amanda, Loges, Sonja, Alt, Jürgen, Joosten, Maria, Schmidtke-Schrezenmeier, Gerlinde, Sebastian, Martin, Stephan-Falkenau, Susann, Waller, Cornelius F., Wiesweg, Marcel, Wolf, Jürgen, Thomas, Michael, Aust, Daniela E., Wermke, Martin
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.11.2021
• Subjects: Checkpoint inhibitor; HER2; Immunotherapy; NSCLC; Checkpoint inhibitor; NSCLC; HER2; Immunotherapy

In contrast to other driver mutations, no targeted therapies have yet been approved in ERBB2-mutated NSCLC (HER2mu NSCLC). Nevertheless, several compounds have revealed promising early efficacy data, which need to be evaluated in the context of current standard approaches. Although data on the effic...